Dupilumab versus placebo significantly reduced concentrations of serum total IgE in AD, asthma, CRSwNP and EoE during treatment; however, across all type 2 diseases, the effect was more gradual than with the other type 2 biomarkers (Table 1 and Figure 4). The gene discussed is IGHE; the disease is eosinophilic esophagitis.